Novavax (NVAX) Reports Positive Phase 1 Data for COVID-19 Vaccine Candidate
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/27/2026
- Wall Street ends higher as investors buy AI stocks; Microsoft rallies
- Stock action shows confidence in central banks: BofA’s Hartnett
- Oil prices slide about 2% as US, Iran explore path out of war
- Why stocks held up despite rising yields and $100 oil? These 2 words explain it
- Barclays asks if equity markets are nearing the boiling point
- White House blocks CNN from Air Force One trip, Washington Post reports
- Merck and Daiichi Sankyo withdraw lung cancer drug application
- Exclusive-SK Hynix's Solidigm weighs IPO that could value the unit at up to $150 billion, sources say
- Wall Street ends higher as investors buy AI stocks; Microsoft rallies
- Fox Factory sells Marucci Sports for $225M, cuts debt
Novavax (NVAX) PT Raised to $257 at B.Riley/FBR
August 5, 2020 6:57 AM EDTB.Riley/FBR analyst Chad L. Mabry raised the price target on Novavax (NASDAQ: NVAX) to $257.00 (from $184.00) while maintaining a Buy rating.
... MoreUPDATE: JPMorgan Upgrades Novavax (NVAX) to Overweight
August 5, 2020 4:40 AM EDT(Updated - August 5, 2020 4:59 AM EDT)
(updating comment)
JPMorgan analyst Eric Joseph upgraded Novavax (NASDAQ: NVAX) from Neutral to Overweight with a price target of $275.00 (from $105.00).
The analyst comments "We are Overweight rated on NVAX shares. Post recent phase 1 results with... More
After-Hours Stock Movers 08/04: (ARPO) (NVAX) (LPSN) Higher; (VAPO) (NEWR) (BYND) Lower (more...)
August 4, 2020 6:07 PM EDTToday's After-Hours Stock Movers
Aerpio Pharmaceuticals, Inc. (Nasdaq: ARPO) 62% HIGHER; Aerpio Pharmaceuticals and The U.S. Government operating through the Medical Technology Enterprise Consortium (MTEC) announced today that an agreement has been reached to evaluate razuprotafib in a new randomized, investigational trial for the prevention and treatment of Acute Respiratory Distress Syndrome (ARDS) in adult patients with moderate to severe COVID-19 as part of MTEC-20-09-COVID-19 Treatment Military Infectious Disease Research Program (MIDRP) Development of Treatments for COVID-19. MTEC will provide up to $5.1 million in... More
Novavax (NVAX) Erases Post-Market Decline, Now Up 13%
August 4, 2020 5:46 PM EDTNovavax (NASDAQ: NVAX) Erases Post-Market Decline, Now Up 13%
Novavax (NVAX) says phase 1 data for COVID-19 vaccine candidate show it was generally well-tolerated and elicited robust antibody responses
August 4, 2020 4:06 PM EDTNovavax, Inc. (NASDAQ: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced Phase 1 data from its Phase 1/2 randomized, observer-blinded, placebo-controlled trial of its COVID19 vaccine with and without MatrixM adjuvant in healthy adults 18-59 years of age. NVXCoV2373, the Companys recombinant COVID-19 vaccine candidate adjuvanted with Matrix-M, was generally well-tolerated and elicited robust antibody responses numerically superior to that seen in human convalescent sera. The data have been submitted for peer-review to a scientific journal and to an online preprint server at... More
Novavax (NVAX) Covid-19 Vaccine Induces Immune Response in First Human Study, Company Says - DJ
August 4, 2020 4:01 PM EDT(Updated - August 4, 2020 4:02 PM EDT)
Novavax (NASDAQ: NVAX) Covid-19 Vaccine Induces Immune Response in First Human Study, Company Says - DJ
Data Supports Further Tests, Plans Large Study in Fall... More